First Comprehensive ADMET Analysis of Kratom Indole Alkaloids Reveals CYP3A4 Inhibition Risk

Why it matters

Kratom users and clinicians need to understand how its alkaloids interact with common drug metabolism enzymes, as these interactions can affect the safety of combining kratom with prescription medications. This is the first study to systematically profile all kratom indole alkaloids in this way.

The big picture

Kratom contains dozens of alkaloids whose pharmacokinetic behavior is poorly understood. Researchers at the University of Alberta and Thammasat University used advanced computational modeling (ADMET Predictor 13.0) to predict how 29 indole alkaloids behave in the body. The findings highlight serious potential for drug interactions — particularly through the CYP3A4 enzyme that processes roughly half of all medications — and set the stage for targeted laboratory validation.

Key findings

• Most kratom indole alkaloids showed strong CYP3A4 substrate interaction and inhibition (79–99% confidence), meaning they could interfere with drugs processed by this enzyme
• All 29 alkaloids showed significant blood-brain barrier penetration (up to 99% confidence), consistent with their psychoactive and analgesic effects
• UGT1A1 — an enzyme important for metabolizing drugs and bilirubin — showed the highest substrate affinity at 97% across alkaloids
• All alkaloids demonstrated strong P-glycoprotein (Pgp) interaction, which can affect how drugs are absorbed and excreted
• Mitralactonal showed the highest intestinal permeability, while Mitralactonine showed the greatest skin absorption potential

What they say

The authors note this investigation "offers the first comprehensive in silico ADMET profiling of kratom indole alkaloids, uncovering their CYP3A4 inhibition potential and metabolic liabilities to prioritize candidates for safer therapeutic development." They caution that experimental in vitro and in vivo validation is still required.

Bottom line

Kratom's indole alkaloids are potent CYP3A4 inhibitors on paper — a finding that signals real drug interaction risks for anyone combining kratom with common medications.